< Back to previous page


Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting

Journal Contribution - Journal Article

Objective: In August 2011, South Africa expanded its adult antiretroviral therapy (ART) guidelines to allow treatment initiation at CD4 cell values 350 cells/mu l or less. Mortality and morbidity are known to be reduced when initiating at higher CD4 levels; we explored the impact on patient loss to follow-up. Design: An observational cohort study. Methods: We analyzed routine data of 1430 adult patients initiating ART from April to December 2010 from a Johannesburg primary healthcare clinic offering ART initiation at CD4 cell count 350 cells/ml or less since 2010. We compared loss to follow-up (>= 3 months late for the last scheduled visit), death, and incident tuberculosis within 1 year of ART initiation for those initiating at CD4 cell values 200 or less versus 201-350 cells/mu l. Results: Half (52.0%) of patients presented in the lower CD4 cell group [< 200 cells/mu l, median: 105 cells/mu l, interquartile range (IQR): 55-154] and initiated ART, and 48.0% in the higher group (CD4 cell count 201-350 cells/mu l, median: 268 cells/mu l, IQR: 239-307). The proportion of women and pregnant women was greater in the high CD4 cell group; the lower CD4 cell group included more patients with prevalent tuberculosis. Among men and nonpregnant women, initiating at 201-350 cells/mu l was associated with 26-42% reduced loss to follow-up compared to those initiating 200 cells/ml or less. We found no CD4 cell effect among pregnant women. Risk of mortality [adjusted hazard ratio (aHR) 0.34, 95% confidence interval (Cl) 0.13-0.84] and incident tuberculosis (aHR 0.44, 95% Cl 0.23-0.85) was lower among the higher CD4 cell group. Conclusion: This is one of the first studies from a routine clinical setting to demonstrate South Africa's 2011 expansion of ART treatment guidelines can be enacted without increasing program attrition. (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins AIDS 2013, 27:645-650
Journal: AIDS
ISSN: 0269-9370
Volume: 27
Pages: 645 - 650
Publication year:2013